Replies to post #21343 on Nutra Pharma Corp (NPHC)

[Millenium323]

That is a 2008 study. Old news

ReceptoPharm Finishes AMN Study
Aug. 05, 2008
ReceptoPharm, a subsidiary of Nutra Pharma, has successfully completed the Phase IIb/IIIa clinical trial of its drug RPI-78M as a treatment for adrenomyeloneuropathy (AMN).

[ClearlyStocks]

ReceptoPharm said it expects to present the study’s findings by the end of next month. It has applied for orphan drug status in the U.S. and intends to do so in the EU.

That sounds good. Will we keep seeing uptrend till the end of the month?